Can-Fite Presentation January 2015
|
|
- Kristian Ferguson
- 5 years ago
- Views:
Transcription
1 Can-Fite Presentation January
2 Forward Looking Statement This presentation contains forward-looking statements, about Can-Fite s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should or anticipate or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission (the SEC ), press releases or oral statements made by or with the approval of one of Can-Fite s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite s filings with the SEC and in its periodic filings with the Tel-Aviv Stock Exchange. 2
3 Company Profile Advanced clinical stage drug development company Phase II and Phase II/III clinical studies Small molecule drugs Autoimmune Inflammatory diseases Cancer Sexual Dysfunction Company Operations Headquarters and Discovery Labs Petach-Tikva, Israel Drug Development & Clinical Operations Boston, USA Two regional out-licensing deals Japan: for inflammation Korea: for rheumatoid arthritis 3 3
4 Equity Profile Ticker on NYSE: CANF Ticker on Israeli TASE: CFBI 1 ADR = 2 Ordinary Shares 52 Week Range: $ $6.75 Shares Out: 21.3M Ordinary Shares Market Capitalization: ~$40M Avg. Trading Volume (30 day): 516,473 ADRs 4
5 From Concept to Technology 5 5
6 Platform Technology Therapeutic Target A3 adenosine receptor (A3AR) Highly expressed in inflammatory and cancer cells Drug product Small molecules Orally bioavailable drugs Therapeutic Effect Anti-inflammatory and anti-cancer effects in Phase II studies; Excellent safety profile A3AR is utilized as Predictive Biomarker Used to predict patient s response to the drug Inflammatory / Tumor Cells Normal Cells A3 Adenosine Receptor (A3AR) Targeted therapy, specifically aimed at diseased cells 6 6
7 Drug Development Pipeline 7 7
8 Market Opportunity* *Global Data, GIA, Visiongain 8 8
9 Corporate Partnership Regional out-licensing deals [Traded on the Tokyo Stock Exchange (Ticker:4548)] Exclusive license to develop and commercialize CF101 in Japan Up to $20 M in upfront, milestone and annual payments ($7.5M received to date) Up to 12% royalties [Traded on South Korean Stock Exchange (Ticker: A009290)] Exclusive regional license to develop and commercialize CF101 for the treatment of rheumatoid arthritis in Korea $1.5 M in upfront and milestone payments ($0.5M received to date) 7% royalties. Such payments are subject to development and marketing milestones Scientific Collaborations Collaborations with two leading medicinal chemistry laboratories in the field of A3AR for supply of new molecules U.S. National Institutes of Health (NIH) Leiden University, the Netherlands 9 9
10 CF101 Anti-Inflammatory Properties Highly Selective A3AR Agonist Nucleoside derivative Molecular weight Water insoluble Orally bioavailable Half life time in blood 8-9 hours Is not metabolized in the body (secreted unchanged) Anti-Inflammatory Effect Proof of concept in pre-clinical pharmacology studies: Rheumatoid Arthritis Osteoarthritis Inflammatory Bowel Disease Uveitis Mechanism of Action CF101 Fishman et al. Drug Discovery Today 17: A3 Adenosine Receptor (A3AR) 10 10
11 Rheumatoid Arthritis - Positive Data from Phase II Study Phase IIb study, Placebo controlled, 79 patients, enrolled based on the biomarker 11 11
12 Psoriasis Positive Data from IA Phase II/III Study Interim analysis after 100 patients Excellent safety profile in all tested dosages Linear improvement along the 24 week study period (PGA-53%; PASI 75-41%) The linear response predicts better PASI &PGA under longer treatment The 2 mg treated group yielded the best response Additional 200 patients were enrolled, 100 placebo and mg, total 300 patients Data are expected in Q Interim Data - PGA Phase II data Before After 12
13 CF102 Anti-Cancer Properties Highly Selective A3AR Agonist Nucleoside derivative Molecular weight Water insoluble Orally bioavailable Half life time in blood 12 hours Anti-Cancer Effect Proof of concept in pre-clinical pharmacology studies: Hepatocellular Carcinoma Colon Carcinoma Prostate Cancer Melanoma Mechanism of Action CF102 A3 Adenosine Receptor (A3AR) 13
14 Liver Cancer Phase II Global Study Ongoing Phase II - Ongoing Patient enrolment for a global Phase II study has been initiated and designed as follows: Second-Line Treatment Advanced Hepatocellular Carcinoma; Child-Pugh B 78 patients; US, Europe and Israel Phase I/II Positive Results Very favorable safety profile and lack of hepatotoxicity Prolongation of survival time Regression of skin tumor metastases Stable disease (22%) Proof of concept for A3AR utilization as a biomarker U.S. FDA Orphan Drug Approval (Feb 2012) Stemmer et al. The Oncologist,
15 CF602 Sexual Dysfunction Properties A3AR allosteric modulator Molecular weight Water insoluble Orally bioavailable Belong to the family of imidazoquinoline derivatives Improving sexual dysfunction Diabetic rat model - Improvement of erectile dysfunction Mechanism of action Untreated Treated with CF602 Current status Pre-Clinical studies - ongoing Cohen et al. Mediators of Inflammation Histological evaluation using a Masson Trichrome stain for smooth muscle detection in Corpus Cavernous blood vessels in an erectile dysfunction model in diabetic rats 15
16 Intellectual Property Portfolio 150 patents issued and pending internationally for inventions including both in-licensed and Can-Fite invented and owned Exclusive licensee of the U.S. National Institutes of Health (NIH) and Leiden University in the Netherlands for patents covering A 3 AR Agonists 15 patent families IP covers composition of matter, synthesis of matter, and clinical applications 16
17 Capitalization / Ownership Table OWNERSHIP TABLE (1) Number of Fully Diluted Shares % of Fully Diluted Shares Holder Name Officers & Directors Pnina Fishman, Ph. D. CEO 569, % Other Officer & Directors 353, % Total Officers & Directors 923, % Israeli Funds / Greater than 5% Ownership Emprey Asset Management L.P. 2,696, % Cranshire Capital Advisors LLC. 2,696, % Total Israeli Funds / Greater than 5% ownership 5,393, % OphthaliX Inc 446, % Public Float 24,165, % TOTAL Fully Diluted Shares 30,929, % CAPITALIZATION TABLE (1) Security type Number Exercise Price (NIS) Index linked Expiration date Common Shares Outstanding (5) 21,763,404 N/A N/A N/A Warrants (3) 1,124,785 (2) No Warrants to PIPE investors 1,080,578 (4) No March 9, 2018 Warrants to December 2014 investors 1,977,528 (4) 8.85 No December Options no. 9 (3) 486, No May 1, 2015 Options no. 10 (3) 1,561, No Oct. 31, 2015 Options no. 11 (3) 1,494, No April 30, 2016 Options no. 12 1,470, No October 22, 2016 Total Fully Diluted 30,929,546 (1) Source: Company Internal Data and Tel-Aviv Stock Exchange Filings (2) Weighted average (3) Adjusted for a 1:25 reverse share split such that split so 1 warrant represented in the table above is currently equal to 25 warrants which are exercisable for 1 ordinary share (4) Exercise price of $2.23 (5) 21,316,577 not including treasury shares 17 17
18 Financials Balance Sheet / Income Statement INCOME STATEMENT (U.S. $ 1 = NIS as of Sep.30, 2014) in thousands $USD LTM of Sep. 30, 2014 Total Revenue - Operating Income ($11,546) The Company raised $8 M in December 2014 The Company has sufficient resources to support its activities for at least the next 12 months EBITDA ($11,533) Net Income / (Loss) ($8,300) BALANCE SHEET (ILS=$USD as of Sep.30, 2014) ASSETS in thousands $USD of Sep. 30, 2014 LIABILITIES & EQUITY in thousands $USD of Sep.30, 2014 Current Assets Current Liabilities Cash & Equivalents $4,118 Trade Payables $682 Accounts Receivable 688 Other accounts payable 779 Non Current Assets 47 Total Current Liabilities 1,461 Total Assets $4,853 Other liabilities 410 Total Liabilities 1,871 Total Equity 2,982 Total Liabilities & Equity $4,853 MONTHLY CASH BURN RATE in thousands $USD Research $30 Development $190 Patent & Royalties $20 G&A $200 Total $
19 Spotlight on 2015 Milestones Indication Milestone Status Biomarker Development of a commercial kit Q CF102 PRIMARY LIVER CANCER PHASE I/II Psoriasis Data from II/III 300 patients study Q Rheumatoid Arthritis Phase III : Regulatory Approvals Q Glaucoma Data from Phase II 88 patients study H CF602 Pre-Clinical studies Q Liver Cancer Finalizing Patient Enrolment for Phase II Trial 78 patients study Q
CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationMichael Anderegg, CFA Senior Research Analyst
Research Update United States Digital Content/Copyright Protection November 19, 2014 Michael Anderegg, CFA Senior Research Analyst Can-Fite BioPharma Ltd. (NYSE MKT: CANF) Late Clinical Stage BioPharma
More informationSmall-Cap Research. Can Fite Biopharma (CANF-NYSE) CANF: Valuation Attractive OUTLOOK
Small-Cap Research November 27, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Can Fite Biopharma (CANF-NYSE) CANF: Valuation Attractive CANF:
More informationINITIATOR PHARMA: Q report
INITIATOR PHARMA: Q1 2018 report Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered
More informationINITIATOR PHARMA: HALF-YEAR REPORT 2017
INITIATOR PHARMA: HALF-YEAR REPORT 2017 Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was
More informationNasdaq: MBRX. Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
Nasdaq: MBRX Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 November 14, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a
More informationARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationINITIATOR PHARMA: Q3 REPORT 2017
INITIATOR PHARMA: Q3 REPORT 2017 Initiator Pharma A/S, a Danish Biotech Company developing a novel treatment of Erectile Dysfunction. Financial Highlights Initiator Pharma A/S is a Danish registered company,
More informationALIZYME PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2000
EMBARGOED FOR RELEASE UNTIL 7:00AM 02 APRIL 2001 ALIZYME PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2000 Alizyme plc, announces its preliminary results for the twelve months ended 31 December
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More information- PRESS RELEASE April 6 th, 2007 PRESS RELEASE April 6 th, PRESS RELEASE -
GENFIT S FINANCIAL RESULTS FOR 2006: PROFITABLE FOR THE 7 TH CONSECUTIVE YEAR DESPITE STRONGER INVESTMENT to the BENEFIT of the DRUG CANDIDATE PIPELINE - Profitable for the 7th consecutive year - Renewed
More informationKitov Pharmaceuticals Streamlined Late-Stage Drug Development
Kitov Pharmaceuticals Streamlined Late-Stage Drug Development Company Presentation December 2015 2015 Kitov pharmaceuticals Ltd. Forward Looking Statements This presentation is not a prospectus or offer
More informationJefferies Healthcare Conference 2016
Jefferies Healthcare Conference 2016 Forward looking Statement This presentation concerning Pluristem Therapeutics may include forward-looking statements which represent Pluristem Therapeutics' expectations
More informationCatabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress -- MoveDMD Trial Data Through One Year of Treatment Reinforce Edasalonexent Potential as Disease-Modifying
More informationNuevolution AB (publ) Presentation Q4 2015/16
Nuevolution AB (publ) Presentation Q4 2015/16 FORWARD-LOOKING STATEMENTS Slide 2 Matters discussed in this presentation may constitute forward-looking statements. Forward-looking statements are statements
More informationSosei Business Update and Revised Financial Forecast Following Acquisition of Arakis
Sosei Business Update and Revised Financial Forecast Following Acquisition of Arakis Tokyo, Japan 16 December 2005: Sosei Co. Ltd ("Sosei" - 4565, Tokyo Stock Exchange MOTHERS index), a leading Japanese
More informationFinancial Results FY2018 Q3
Financial Results FY2018 Q3 (January to September 2018) Carna Biosciences, Inc. Stock Code:4572 1 FY2018 Q3 Key Highlights Established the clinical development team to initiate clinical trials of Carnaʼs
More informationRegeneron Reports Third Quarter 2010 Financial Results and Business Highlights
Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights TARRYTOWN, N.Y., Oct 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today
More informationLeading the world in novel adult stem cell therapies Half-Year Financial Results
Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following
More informationIntec. Pharma Unfolding drug delivery solutions. Investor Presentation. Nasdaq: NTEC. June 2017
Intec Pharma Unfolding drug delivery solutions Investor Presentation Nasdaq: NTEC June 2017 Forward Looking Statements This presentation by Intec Pharma Ltd. (referred to as we or our ) contains forward-looking
More informationINVESTOR PRESENTATION FULL YEAR 2007 RESULTS. February 2008
INVESTOR PRESENTATION FULL YEAR 2007 RESULTS February 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may, would,
More informationMustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY November 13, 2018 Mustang Bio, Inc. ( Mustang ) (NASDAQ: MBIO), a company focused on the development
More informationA Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited
A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata or
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationMarch 13, Dear Shareholder:
15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 March 13, 2017 Dear Shareholder: We would like to take this time to report on the business activities and accomplishments of RegeneRx in
More informationLoxo Oncology Announces Third Quarter 2016 Financial Results
Loxo Oncology Announces Third Quarter 2016 Financial Results November 2, 2016 Updated LOXO-101 Phase 1 Clinical Data Accepted for Oral Presentation at ESMO Asia on December 18, 2016 Company to Provide
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationFuriex Pharmaceuticals
Furiex Pharmaceuticals NASDAQ: FURX June Almenoff MD, PhD President & Chief Medical Officer Bio CEO & Investor Conference February 2011 Forward-Looking Statements This presentation includes forward-looking
More informationCombining Capabilities to Serve More Patients with Rare Diseases
Combining Capabilities to Serve More Patients with Rare Diseases Filed by BioCryst Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under
More informationform of testing is used and is
Universal Biosensors, Inc. ABN 51 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone: +61 3 9213 9000 Facsimile: +61 3 9213 9099 Email: info@universalbiosensors.com www.universalbiosensors.com
More informationMomenta Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017 Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results --Company reports Glatopa 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the
More informationpsivida Corp PSDV June 2016
psivida Corp PSDV June 2016 Safe Harbor Statement Safe Harbor Statement SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking,
More informationImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
More informationi-bodies a new class of protein therapeutics to treat human disease
i-bodies a new class of protein therapeutics to treat human disease AGM November 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More informationBY PEOPLE. WITH PEOPLE. FOR PEOPLE.
BY PEOPLE. WITH PEOPLE. FOR PEOPLE. :: 4SC AG, ENNO SPILLNER KORRELATION UNTERNEHMENSNACHRICHTEN & UNTERNEHMENSBEWERTUNG BERLIN, 19. MÄRZ 2013 FORWARD LOOKING STATEMENTS This presentation may contain projections
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Investor Presentation April 2011 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive
More informationINITIATOR PHARMA: PREPARING FOR THE CLINICAL PHASE
YEAR END REPORT FOR INITIATOR PHARMA A/S INITIATOR PHARMA: PREPARING FOR THE CLINICAL PHASE Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation
More informationMedivir Corporate Presentation December, A research-based pharmaceutical company focused on infectious diseases and oncology
Medivir Corporate Presentation December, 2015 A research-based pharmaceutical company focused on infectious diseases and oncology 2 Balanced platform of innovation and revenue generation Locations and
More information2017 KEY MILESTONES AND 2018 OUTLOOK
OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products Key Clinical Portfolio Development Progress Planned for 2018 Tedopi (neoepitopes): Phase 3 clinical
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationSobi Update and Perspective Jefferies Healthcare Conference
Sobi Update and Perspective Jefferies Healthcare Conference Geoffrey McDonough CEO London 19 November 2014 Forward Looking Statements In order to utilize the Safe Harbor provisions of the United States
More information35 th Annual J.P. Morgan Healthcare Conference. Gwan Sun Lee. President & CEO
35 th Annual J.P. Morgan Healthcare Conference Gwan Sun Lee President & CEO This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses
More informationKaryopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
August 4, 2016 Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma On Track to
More informationPhysiomics Plc. ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2015
The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 ("Physiomics" or "the Company") Interim Results Statement for the six month period
More informationNovel targets, better molecules
Novel targets, better molecules Investor Presentation November 2014 Copyright 2014 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for
More informationSelecta Biosciences Announces Third Quarter 2016 Financial Results and Provides Corporate Update
Selecta Biosciences Announces Third Quarter 2016 Financial Results and Provides Corporate Update November 10, 2016 7:00 AM ET Phase 2 Trial of SEL-212 for Treatment of Gout Initiated SEL-212 Phase 1 Clinical
More informationBioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
November 9, 2018 BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update NEW HAVEN, Conn., Nov. 09, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ( BTI ) (Nasdaq:
More informationPROVECTUS BIOPHARMACEUTICALS INC. ANALYST BRIEF A NEW FRONT AGAINST CANCER
Summary Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) is a biopharmaceutical company whose planned principal operations is focusing on developing minimally invasive products for the treatment of psoriasis
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationAllergan to Acquire Naurex
NEWS RELEASE CONTACTS: ALLERGAN: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 NAUREX: Canale Communications Pam Lord pam@canalecomm.com 619-849-6003 Naurex Inc. Ashish Khanna
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More informationMarket Analysis & Segmentation. Gary Phillips CEO Bioshares 29 July 2016
Market Analysis & Segmentation Gary Phillips CEO Bioshares 29 July 2016 1 Forward looking statement This document contains forward looking statements, including statements concerning Pharmaxis future financial
More informationABLYNX ANNOUNCES Q BUSINESS UPDATE
REGULATED INFORMATION ABLYNX ANNOUNCES Q1 2014 BUSINESS UPDATE GHENT, Belgium, 14 May 2014 - Ablynx [Euronext Brussels: ABLX] today announced its non-audited business update, summarising Ablynx s financial
More informationActive Biotech Interim Report April-June 2002
Active Biotech Interim Report April-June 2002 SAIK-MS Phase II trial in patients proceeding according to plan TTS Phase II cancer studies advancing according to plan renal and pancreatic cancer patients
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationCymaBay Therapeutics (CBAY)
Company Update CymaBay Therapeutics (CBAY) CymaBay Finds Success in Phase II Study for Seladelpar, Observed Drug Profile is Likely Competitive. On July 17 th, CymaBay Therapeutics (NasdaqCM: CBAY) announced
More informationOn Helix. 02 July Harren Jhoti President & CEO
On Helix 02 July 2014 Harren Jhoti President & CEO Astex Pharmaceuticals Global developer of small molecule drugs for unmet medical needs Expertise in oncology discovery & development World-class fragment-based
More information2016 Summary Financial Results
ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE -------------------------------------------------------------------------------------------------- GENETIC-AF Phase
More informationCorporate Presentation. Roberto Bellini President and Chief Executive Officer
Corporate Presentation Roberto Bellini President and Chief Executive Officer September 2012 Forward Looking Statement Certain statements contained in this presentation, other than statements of fact that
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationAkcea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCapstone Therapeutics (Trade Name of OrthoLogic Corp.)
AZX100 AZX100 Capstone Therapeutics (Trade Name of OrthoLogic Corp.) Corporate Overview October 2009 1 Safe Harbor Statement Statements in this presentation or otherwise attributable to Capstone Therapeutics
More informationCORPORATE NEWS FINANCIAL RESULTS 2017 PAION AG REPORTS ON FISCAL YEAR 2017 AND FINANCIAL RESULTS
CORPORATE NEWS FINANCIAL RESULTS 2017 PAION AG REPORTS ON FISCAL YEAR 2017 AND FINANCIAL RESULTS Phase III program for remimazolam in the U.S. completed Partnership announced with Mundipharma for Japan
More information11th Annual BIO CEO & Investor Conference
11th Annual BIO CEO & Investor Conference John L. Higgins President and Chief Executive Officer Martin Meglasson Vice President of Discovery Research 1 Safe Harbor Statement During the course of this presentation,
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationChiome Bioscience Inc TSE Mothers
Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪伪 Succeeded in generating antibodies for the Ebola virus and is accelerating development in the field of pandemic contagious diseases
More informationAdvancing the Frontiers of mab mixtures
Advancing the Frontiers of mab mixtures...unlocking the power of the immune system Symphogen Corporate Presentation June 216 Symphogen/1 Symphogen Overview Privately held company - 125 employees Headquarters
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More information14 May Evotec Q1 2013: Driving Innovation Efficiency
14 May 2013 Evotec Q1 2013: Driving Innovation Efficiency STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY EVOTEC S DRUG DISCOVERY PLATFORM GENERATES GROWTH NEW HORMONE IDENTIFIED
More informationPeregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
September 3, 2009 Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010 - Advances Achieved in All Six Bavituximab and Cotara(R) Cancer Clinical Studies - - Total
More informationInventiva: acceleration of the clinical development activities and consolidation PRESS RELEASE of the financial position in 2016
COMMUNIQUE DE PRESSE Inventiva: acceleration of the clinical development activities and consolidation PRESS RELEASE of the financial position in 2016 Launch of IVA337 Phase IIb trial in NASH Initiation
More informationHSCI: the first Russian public biotech company
HSCI: the first Russian public biotech company (expanding into new geographic markets) TEASER for Investor presentation (road-show for sale of 28.6 % of HSCI s increased share capital) June 2014 Disclaimer
More informationInterim Results 19 September 2005
Interim Results 19 September 2005 www.alizyme.com Presentation by Dr Richard Palmer, Chief Executive Officer Tim McCarthy, Finance Director Important This presentation has been organised by Alizyme plc
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationSage Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More informationPharmaMar A Biopharmaceutical Company
From Marine Expeditions to New Drugs in Oncology 26 June, 2007 Contents PharmaMar A Biopharmaceutical Company BioDiversity: The Business Case The Current Research Environment Value Creation: The R&D Process
More informationIntellectual Property and Academic- Industrial Collaboration
Intellectual Property and Academic- Industrial Collaboration J. Denry Sato, D.Phil Visiting Professor of Industry-Academia- Government Collaboration Hiroshima University Funding Problem for Educational
More informationPieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update
March 22, 2016 Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update Company to Host an Investor Conference Call on Wednesday, March 23, 2016 at 10:00 AM ET BOSTON, MA --
More informationCapital Raising Presentation January 2017
Capital Raising Presentation January 2017 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available to it as at the
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationAstellas to Acquire Agensys, Inc.
November 27, 2007 to Acquire, Inc. Japan, November 27, 2007 - Pharma Inc. ( ; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that its US subsidiary, US Holding, Inc. (headquarters:
More informationCorporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 ASX Spotlight Conference October 2012 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive
More informationARCUSBIOSCIENCES,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,DC20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d) ofthesecuritiesexchangeactof1934 DateofReport(Dateofearliesteventreported):May9,2018 ARCUSBIOSCIENCES,INC.
More informationBioCryst Reports Fourth Quarter and Full Year 2017 Financial Results. Updates Investors Regarding Proposed Merger with Idera Pharmaceuticals, Inc.
BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results Updates Investors Regarding Proposed Merger with Idera Pharmaceuticals, Inc. Research Triangle Park, North Carolina February 27, 2018
More informationA Next Generation Stem Cell Company
A Next Generation Stem Cell Company Dr. Ross Macdonald, CEO Cynata Therapeutics Limited Proactive Investor Lunch, March 2017 Important Information This presentation has been prepared by Cynata Therapeutics
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationPresentation to J.P. Morgan 33rd Annual Healthcare Conference. Moshe Manor President and CEO January 15, 2015
Presentation to J.P. Morgan 33rd Annual Healthcare Conference Moshe Manor President and CEO January 15, 2015 1 Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More information